Last reviewed · How we verify

VONVENDI — Competitive Intelligence Brief

VONVENDI (VONVENDI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant von Willebrand factor. Area: Hematology.

marketed Recombinant von Willebrand factor von Willebrand factor (VWF) Hematology Biologic Live · refreshed every 30 min

Target snapshot

VONVENDI (VONVENDI) — Takeda. VONVENDI is a recombinant von Willebrand factor (VWF) that replaces deficient or dysfunctional VWF to restore platelet adhesion and hemostasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VONVENDI TARGET VONVENDI Takeda marketed Recombinant von Willebrand factor von Willebrand factor (VWF)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant von Willebrand factor class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VONVENDI — Competitive Intelligence Brief. https://druglandscape.com/ci/vonvendi. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: